Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    Lifelong GLP-1s? The debate over long-term use

    Trials show most of the weight lost on GLP-1 drugs returns after they are stopped, which implies long-term treatment for many people.[1][2] How safe, affordable and necessary decades of use will be is not yet known. Evidence on muscle, nutrition and rare side effects is still building.[3][4]

    Editor reviewedStrict sourcingUpdated GLP-1 and metabolic medicineHealth and medicine
    Show:

    If obesity is a chronic disease, the drugs that treat it may need to be taken indefinitely, as blood-pressure or cholesterol drugs are.[5] That prospect raises questions about safety over decades, cost, and whether drugs alone are the right model. This page sets out what is known as of October 2026.

    What happens when treatment stops

    In the STEP 1 extension, participants who stopped semaglutide and lifestyle support regained about two-thirds of their prior weight loss within a year. Most cardiometabolic improvements reverted toward baseline.[1] In SURMOUNT-4, people who lost a mean 20.9% on tirzepatide and then switched to placebo regained 14.0% over 52 weeks. Those who continued lost a further 5.5%.[2] A 2026 BMJ meta-analysis of 37 studies estimated regain of 0.4 kg a month after stopping weight-management medicines. It projected cardiometabolic markers to return to baseline within 1.4 years, faster than after behavioural programmes.[6]

    Switching rather than stopping is now being tested. In ATTAIN-MAINTAIN, people who had lost weight on tirzepatide or semaglutide injections and moved to the orforglipron pill kept an estimated 74.7% and 79.3% of their weight loss at 52 weeks, versus 49.2% and 37.6% on placebo.[7] The authors noted that the trial had no arm that stayed on injections and lasted only a year.[8]

    What is known about safety and body composition

    Gastrointestinal side effects are common and lead many people to stop. In SELECT, 16.6% on semaglutide discontinued for adverse events versus 8.2% on placebo.[9] At the top retatrutide dose in TRIUMPH-1, the figure was 11.3% versus 4.9%.[10] Rare harms emerge with wide use: in 2025 the EMA listed NAION, a form of sudden vision loss, as a very rare side effect of semaglutide.[4] A 2026 review on nutrition and lean mass found responses vary between people. It recommended a risk-based approach for groups such as older adults rather than routine supplementation for all.[3]

    On the benefit side, outcome trials found fewer cardiovascular events (SELECT), fewer major kidney events (FLOW) and better liver histology (ESSENCE) during treatment periods of up to about three to four years.[11][12][13] WHO’s 2025 guideline gives only conditional recommendations, partly because long-term data are limited.[14]

    How to read it

    The withdrawal data are consistent. Stopping usually means regain, so the practical choice for many patients is between continuing treatment and accepting regain. That links this debate directly to price: lifelong use at today’s prices is a very different budget question from a one-year course.[6][15]

    The evidence gaps are mostly about duration and populations. Outcome trials ran for years, not decades. Body-composition and nutrition effects appear to vary by person. Rare adverse events are still being characterised through post-marketing surveillance.[11][3][4]

    What to watch

    Likely developments: more data on maintenance strategies, such as lower doses or switching to pills after injections; longer follow-up from outcome trials; and safety signals from regulators as use grows. More potent drugs such as retatrutide, which Lilly plans to file in 2027, will sharpen questions about how much weight loss is desirable and for whom. These are expectations, not established findings.[16][17] Unapproved retatrutide is already sold illegally online, which Lilly is contesting in court, so long-term use questions are arising before approval.[18]

    Competing views

    Treat it like blood pressure

    Obesity is a chronic, relapsing disease. Withdrawal trials show regain, and outcome trials show benefits during treatment, so continuous therapy is the logical default.[5][2][11]

    Use drugs within a broader programme

    Regain after stopping is faster than after behavioural programmes, so drugs should come with structured behavioural support and attention to nutrition and muscle, not as a stand-alone fix.[6][14][3]

    Long-term safety is not yet proven

    Trials last one to four years, side effects cause many people to stop, and rare harms surface only with wide use. Caution is warranted before assuming decades of treatment.[9][4][14]

    Questions readers ask

    What happens to weight after stopping semaglutide?

    In the STEP 1 extension, people regained about two-thirds of their prior weight loss within a year of stopping, and most cardiometabolic improvements reverted toward baseline.[1]

    How fast is weight regained after stopping weight-loss medicines?

    A 2026 BMJ meta-analysis of 37 studies estimated average regain of 0.4 kg per month, faster than after behavioural programmes.[6]

    Do GLP-1 drugs cause muscle loss or malnutrition?

    A 2026 review found that nutritional and muscle responses vary between people. It said routine supplementation is not supported for everyone but a risk-based approach is appropriate for groups such as older adults.[3]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      One year after stopping semaglutide and lifestyle intervention in the STEP 1 extension, participants had regained about two-thirds of their prior weight loss, and most cardiometabolic improvements reverted toward baseline. confirmedas of 2022-05-19

    2. [2]

      In SURMOUNT-4, people who lost a mean 20.9% during a 36-week tirzepatide lead-in and were then switched to placebo regained 14.0% of body weight over the next 52 weeks, while those who continued lost a further 5.5%. confirmedas of 2024-01-01

    3. [3]

      A 2026 narrative review concluded that nutritional and muscle effects of GLP-1-based therapy vary between people, and that routine supplementation is not supported for all patients but a risk-based approach is appropriate for groups such as older adults. confirmedas of 2026-08-23

    4. [4]

      In June 2025 the EMA's safety committee recommended listing NAION, a form of sudden vision loss, as a very rare side effect of semaglutide medicines, affecting up to 1 in 10,000 people. confirmedas of 2025-06-06

    5. [5]

      WHO's 2025 guideline describes obesity as a chronic, relapsing disease that needs comprehensive, lifelong care rather than medication alone. confirmedas of 2025-12-01

    6. [6]

      A 2026 BMJ meta-analysis of 37 studies found average weight regain of 0.4 kg per month after stopping weight-management medicines, with cardiometabolic markers projected to return to baseline within 1.4 years, faster than after behavioural programmes. confirmedas of 2026-01-07

    7. [7]

      In the phase 3b ATTAIN-MAINTAIN trial, people who switched from injectable tirzepatide or semaglutide to daily orforglipron kept an estimated 74.7% and 79.3% of their prior weight loss at 52 weeks, versus 49.2% and 37.6% with placebo. confirmedas of 2026-05-13

    8. [8]

      The ATTAIN-MAINTAIN authors noted that the trial had no comparator arm continuing injectable obesity medicines and lasted only one year. confirmedas of 2026-05-13

    9. [9]

      In SELECT, adverse events led to permanent discontinuation in 16.6% of semaglutide patients versus 8.2% on placebo. confirmedas of 2023-11-11

    10. [10]

      In TRIUMPH-1, discontinuation due to adverse events was 11.3% at the 12 mg retatrutide dose versus 4.9% with placebo; the most common adverse events were gastrointestinal. confirmedas of 2026-05-21

    11. [11]

      In the SELECT trial of 17,604 adults aged 45 or older with cardiovascular disease and overweight or obesity but no diabetes, semaglutide 2.4 mg reduced cardiovascular death, heart attack or stroke to 6.5% versus 8.0% on placebo (hazard ratio 0.80). confirmedas of 2023-11-11

    12. [12]

      In the FLOW trial of 3,533 people with type 2 diabetes and chronic kidney disease, semaglutide lowered the risk of major kidney events or kidney- or cardiovascular-related death by 24% (hazard ratio 0.76); the trial stopped early at a prespecified interim analysis after a median 3.4 years of follow-up. confirmedas of 2024-05-24

    13. [13]

      In part 1 of the ESSENCE trial in people with MASH and moderate or advanced liver fibrosis, steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide versus 34.3% on placebo at 72 weeks, in a planned interim analysis of the ongoing 240-week trial based on liver histology. confirmedas of 2025-04-30

    14. [14]

      On 1 December 2025 WHO issued its first guideline on GLP-1 medicines for obesity, with conditional recommendations that adults may use them for long-term treatment alongside behavioural interventions. confirmedas of 2025-12-01

    15. [15]

      A 2026 German health-economic model estimated that tirzepatide for obesity-related heart failure with preserved ejection fraction cost about EUR 252,611 per quality-adjusted life year at current prices, and concluded substantial price cuts would be needed. confirmedas of 2026-05-19

    16. [16]

      As of August 2026, Lilly said three additional phase 3 retatrutide obesity trials were positive, that the data package was complete for obesity, obstructive sleep apnea and knee osteoarthritis pain, and that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. confirmedas of 2026-08-05

    17. [17]

      The peer-reviewed TRIUMPH-1 report (NEJM, 29 September 2026) gave mean weight changes at 80 weeks of -17.6%, -23.7% and -25.0% with retatrutide 4, 9 and 12 mg versus -3.9% with placebo under the treatment-regimen (intention-to-treat) estimand; Lilly's May topline figures of 19.0%, 25.9% and 28.3% used the efficacy estimand. confirmedas of 2026-09-29

    18. [18]

      In August 2026 Lilly said no retatrutide medicine had been approved anywhere, filed six lawsuits against US sellers of black-market retatrutide and said it had reported more than 14,000 websites, ads and listings marketing it illegally. confirmedas of 2026-08-12

    Revision history (2)
    1. Page created.
    2. Refresh: added ATTAIN-MAINTAIN switch-to-pill evidence and the black-market retatrutide issue.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Lifelong GLP-1s? The debate over long-term use." ContentLora, updated Oct 10, 2026. https://contentlora.com/analysis/glp-1-long-term-use-debate

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents